Welcome to our dedicated page for Eloxx Pharmaceut SEC filings (Ticker: ELOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eloxx Pharmaceut's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eloxx Pharmaceut's regulatory disclosures and financial reporting.
Eloxx Pharmaceuticals furnished an Information Statement reporting that majority stockholders approved, by written consent, (1) increases and an amendment to its 2018 Equity Incentive Plan and (2) a reverse stock split authorizing a ratio between 1-for-2 and 1-for-20, with the Board to select the exact ratio on or prior to the one-year anniversary of the Record Date.
The Company states 7,573,935 shares of Common Stock were outstanding as of the Record Date of April 28, 2026. The First Amendment raised the plan Share Reserve to 20,000,000 shares (noting the Restated Plan shows a Share Reserve of 19,240,639) and increases the ISO limit ultimately to 80,000,000 shares; the Restated Plan extends the evergreen provision through January 1, 2036 and permits ISOs through April 27, 2036. The filing notes an OTC Experts Markets closing price of $0.084 per share on April 17, 2026.